Anthropic, an AI company preparing for a potential $2 trillion IPO, reported a massive $80.7 billion net loss in the first half of 2026, mainly due to accounting charges. The company warned that growing organized opposition to data center construction, especially in the US, could threaten its business expansion. Despite surging revenue to $16.3 billion, Anthropic faces high costs and dependency on a few large clients. Experts suggest the backlash may not derail the IPO but could pose long-term regulatory risks as the AI market matures.
Anthropic's reported $80.7 billion net loss in H1 2026 provides context for readers following the AI sector. For readers following Technology-sector US stocks on Pluang, here is the market snapshot as of Oct 21, 2026 04:41 WIB: out of 150 stocks, 123 rose and 25 fell. Notable movers include HUBS at USD 250.00 (+6.57%, 79 days typical hold time, 100% sell orders), EGHT at USD 2.13 (+6.50%, 17 days hold, 100% sell), and MSTR at USD 144.70 (+6.38%, 113 days hold, 70% sell / 30% buy).
Medical Informatics Corp. has launched the Sickbay Experience Demo Center at Texas Medical Center's Helix Park, showcasing its FDA-cleared Sickbay platform. This interactive center demonstrates how real-time patient data from various medical devices ...
Grupo Aeroportuario del Pacífico reported Q3 2026 earnings per share of $2.66 and revenue of $632.9 million, both below analyst expectations. Despite the miss, the company saw a 13.2% rise in revenue excluding construction services and a 19.2% increa...
Northern Trust is set to report its Q3 2026 earnings with analysts forecasting a 24.9% rise in earnings per share to $2.86 and an 11.8% increase in revenue to $2.26 billion. Growth is driven by an 11.4% increase in net interest income and a 12.1% ris...
Moody's is expected to report Q3 2026 earnings of around $4.25 per share on revenue near $2.08 billion, driven by steady demand for credit ratings and growth in Moody's Analytics, especially from recurring subscriptions and AI tools. While Moody's In...
Raymond James increased its price target for Rapport Therapeutics to $86 following positive Phase 2 trial results of RAP-219, a drug treating acute bipolar mania. The trial showed statistically significant improvement in patients and a favorable safe...
